The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

The present invention provides novel inhibitors of MIF tautomerase activity. In certain embodiments, the compounds of the invention are useful in treating or preventing inflammatory and/or auto-immune diseases. In other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing tumor growth. In yet other embodiments, the compounds of the invention are useful in reversing, ameliorating, and/or preventing angiogenesis.

This invention relates to a catalyst for preparing a cyclic hydrocarbon, which is a non-noble-metal supported on zirconium phosphate, and to a method of preparing a cyclic hydrocarbon, including preparing a cyclic hydrocarbon from a lignin derivative through hydrodeoxygenation and hydrogenation using the catalyst for preparing a cyclic hydrocarbon.

This invention relates to a catalyst for preparing a cyclic hydrocarbon, which is a non-noble-metal supported on zirconium phosphate, and to a method of preparing a cyclic hydrocarbon, including preparing a cyclic hydrocarbon from a lignin derivative through hydrodeoxygenation and hydrogenation using the catalyst for preparing a cyclic hydrocarbon.

A method for preparing a ruthenium catalyst, including a step of reducing a ruthenium catalyst precursor by holding the ruthenium catalyst precursor in an aqueous solution containing a metal salt at a temperature within the range of more than 180 C. and 220 C. or less and a hydrogen partial pressure within the range of 0.6 MPa or more and 5 MPa or less. A method for producing a cycloolefin, including a step of preparing a ruthenium catalyst by the method including a step of reducing a ruthenium catalyst precursor in an aqueous solution containing a metal salt by holding the ruthenium catalyst precursor at a temperature within the range of more than 180 C. and 220 C. or less and a hydrogen partial pressure within the range of 0.6 MPa or more and 5 MPa or less, and a step of partially hydrogenating a monocyclic aromatic hydrocarbon by use of the ruthenium catalyst obtained.

A method for preparing a ruthenium catalyst, including a step of reducing a ruthenium catalyst precursor by holding the ruthenium catalyst precursor in an aqueous solution containing a metal salt at a temperature within the range of more than 180 C. and 220 C. or less and a hydrogen partial pressure within the range of 0.6 MPa or more and 5 MPa or less. A method for producing a cycloolefin, including a step of preparing a ruthenium catalyst by the method including a step of reducing a ruthenium catalyst precursor in an aqueous solution containing a metal salt by holding the ruthenium catalyst precursor at a temperature within the range of more than 180 C. and 220 C. or less and a hydrogen partial pressure within the range of 0.6 MPa or more and 5 MPa or less, and a step of partially hydrogenating a monocyclic aromatic hydrocarbon by use of the ruthenium catalyst obtained.